Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01411501
Other study ID # 2011CB505202
Secondary ID
Status Completed
Phase Phase 3
First received July 28, 2011
Last updated November 8, 2015
Start date September 2011
Est. completion date December 2014

Study information

Verified date November 2015
Source Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Contact n/a
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

A multi-center clinical trial done recently by us(NCT00508482) shows that needling on ST25 has the same effect as lactulose in unaided self-defecation frequency of a week and has better effect in symptoms improvement (in press). The object is to evaluate whether acupuncture is effective for functional constipation. As an explanatory research, it took one single point as its intervention and sham acupuncture as its control group (patients were blinded). On the basis of its confirmed effect, we are taking a pragmatic randomized controlled trial to further evaluate whether acupuncture is more effective than routine treatment. Acupuncture prescriptions used in this trial are individually prescribed according to syndrome differentiation, which can improve clinical effect. .


Description:

functional constipation,acupuncture,effects and safety,pragmatic RCT


Recruitment information / eligibility

Status Completed
Enrollment 684
Est. completion date December 2014
Est. primary completion date October 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Patients who has been diagnosed with functional constipation according to Rome ? criteria

- Patients who are aged 18-75 years old

- Stop medication or acupuncture (if any) 1 week before randomization and uninvolved in other trials

- Sign the informed consent out of one's own will

Exclusion Criteria:

- Secondary constipation

- Patients with consciousness impairment, psychotic patients or patients unable to express clearly

- Patients with malignant tumor in progressive stage, severe wasting disease and liable to be infected and bleed

- Patients with severe cardiovascular disease, hepatic injury, renal damage, digestive disease or hematological diseases

- Women in pregnancy and lactation period

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Other:
acupuncture
Thrust and lift the needle to achieve De Qi. After being needled, the points will be punctured again using auxiliary needles 2 mm lateral to the first needle, and to a depth of 2 mm without manual stimulation. Put the electric stimulator on the pair of needles with a continuous wave, 20Hz. The current intensity is increased to the patients' maximum tolerance and then slightly reduced to a bearable level (0.1-1.0 mA). Huatuo Brand needle (f0.30×25mm,f0.30×40mm,f0.30×50mm, produced by Suzhou Medical Appliance Factory) and G6805-1A electro-acupuncture apparatus(produced by Shanghai Huayi Medical Instrument Co. Ltd.) will be used. Five sessions/week in the first 2 weeks, three sessions/week for in the last 2 weeks.
Drug:
mosapride citrate
4-week oral use of mosapride citrate, 5mg, three times daily 0.5 hour before meal

Locations

Country Name City State
China No.5 Beixiange Street, Xuanwu District Beijing

Sponsors (2)

Lead Sponsor Collaborator
Guang'anmen Hospital of China Academy of Chinese Medical Sciences Ministry of Science and Technology of the People´s Republic of China

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of the SBMs From Baseline at Week 4 [average number of spontaneous bowel movements in a week at week 4]-[average number of spontaneous bowel movements in a week at baseline] baseline and at 4 weeks Yes
Secondary Change From Baseline in the Bristol Stool Scale at the 4th Week Bristol stool scale provides illustration of seven stool types. It ranges from 1 to 7 with the meaning that 1 referring to separate hard lumps and 7 referring to watery, no solid pieces. For patients with constipation, a higher score means a better outcome. This outcome means the Bristol Stool Scale at the 4th week-the Bristol Stool Scale at baseline. baseline and at 4 weeks Yes
Secondary Change From Baseline in Difficulty Degree of Defecation at the 4th Week This outcome describes how much effort the patients with while defecating.It ranges from 0 to 3.
0—Without difficulty
Defecation straining
Severe defecation straining
Defecation with the help of hands, A 0 is considered better than 3 for outcome. Patients score for themselves according to their own feelings.
[the average score of one week at the 4th week]-[the average score of one week at baseline]
baseline and at 4 weeks No
Secondary Changes of the SBMs From Baseline at Week 8 [average number of spontaneous bowel movements in a week at week 8]-[average number of spontaneous bowel movements in a week at baseline] baseline and at 8 weeks No
Secondary Change From Baseline in the Bristol Stool Scale at the 8th Week Bristol stool scale provides illustration of seven stool types. It ranges from 1 to 7 with the meaning that 1 referring to separate hard lumps and 7 referring to watery, no solid pieces. For patients with constipation, a higher score means a better outcome. This outcome means the Bristol Stool Scale at the 8th week-the Bristol Stool Scale at baseline. baseline and at 8 weeks No
Secondary Change From Baseline in Difficulty Degree of Defecation at the 8th Week This outcome describes how much effort the patients with while defecating. It ranges from 0 to 3.
0—Without difficulty
Defecation straining
Severe defecation straining
Defecation with the help of hands, A 0 is considered better than 3 for outcome. Patients score for themselves according to their own feelings.
[the average score of one week at the 8th week]-[the average score of one week at baseline]
baseline and at 8 weeks No
See also
  Status Clinical Trial Phase
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Recruiting NCT06292949 - Clinical Study of Resistant Starch in Improving Constipation N/A
Recruiting NCT04132661 - MRI Assessment of Mode of Action of Bisacodyl, Single Dose Phase 4
Terminated NCT02839889 - Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation) Phase 4
Completed NCT02726295 - The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study Phase 4
Recruiting NCT02255747 - Anal Dilatation for Infants and Children With Constipation N/A
Completed NCT02246647 - Biomarkers for Intestinal Permeability in Patients With Constipation
Completed NCT01566409 - Maintenance Treatment for Children With Constipation N/A
Completed NCT02658201 - Ultrafast MRI Imaging to Exclude Constipation N/A
Completed NCT01695915 - Diurnal Variation in Rectal Diameter N/A
Completed NCT01710579 - Normal Values in Ano-rectal 3D High Resolution Manometry N/A
Completed NCT02863848 - Effect of Inulin-type Fructans on Constipated Children. N/A
Completed NCT01474499 - A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation Phase 3
Completed NCT01438567 - A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy Phase 3
Completed NCT00931853 - Efficacy and Tolerability of Cassia Fistula Plus Senna Alexandrina Miller (Sugar Free) in the Chronic Functional Constipation (CFC). Phase 3
Completed NCT01170039 - The Effectiveness of Lubiprostone in Constipated Diabetics Phase 4
Active, not recruiting NCT02442115 - Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress
Completed NCT00994851 - Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment. Phase 3
Terminated NCT01003249 - Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen Phase 4
Completed NCT01607060 - Impact of Laxative Therapy With Lactulose in the Evolution of Organ Dysfunction in Critically Ill Patients. Phase 3